A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Coronel, Jaime ^a   Cetina, Lucely ^a   Pacheco, Irlanda ^a   Trejo Becerril, Catalina ^a   González Fierro, Aurora ^a   De La Cruz Hernandez, Erick ^a   Perez Cardenas, Enrique ^a   Taja Chayeb, Lucia ^a   Arias Bofill, Daymi ^a   Candelaria, Myrna ^a   Vidal, Silvia ^a   Dueñas González, Alfonso ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Advanced cervical cancer; Epigenetic therapy; Randomized phase III

Indexed keywords

CISPLATIN; HYDRALAZINE; PLACEBO; TOPOTECAN; VALPROATE MAGNESIUM;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; EDEMA; EPIGENETIC THERAPY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; UTERINE CERVIX CANCER; VERTIGO; VOMITING;

EID: 84655175030     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9700-3     Document Type: Article

References (42)

1. A Dueñas-González 2005 Epigenetics of cervical cancer. An overview and therapeutic perspectives Mol Cancer 4 38
2. BJ Monk 2009 Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 4649 4655
3. A Dueñas-González L Cetina J Coronel D Martínez- Baños 2010 Pharmacotherapy options for locally advanced and advanced cervical cancer Drugs 70 403 432
4. WG Zhu GA Otterson 2003 The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells Curr Med Chem Anti-Cancer Agents 3 187 189
5. EE Cameron KE Bachman S Myohanen JG Herman SB Baylin 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 103 107 (Pubitemid 29036293)
6. WG Zhu 2001 DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors Cancer Res 61 1327 1333
7. DM Hellebrekers AW Griffioen M van Engeland 2007 Dual targeting of epigenetic therapy in cancer Biochim Biophys Acta 1775 76 91 (Pubitemid 44895568)
8. B Segura-Pacheco 2003 Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy Clin Cancer Res 9 1596 1603 (Pubitemid 36554581)
9. Y Song C Zhang 2009 Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression" Cancer Chemother Pharmacol 63 605 613
10. AY Law CK Ip AS Wong GF Wagner CK Wong 2008 Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells Exp Cell Res 314 1823 1830
11. X Wang 2009 Association between CpG island methylation of the WWOX gene and its expression in breast cancers Tumor Biol 30 8 14
12. A Chavez-Blanco 2006 Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines Cancer Cell Int 6 2
13. H Li 2008 Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSF1A and P16 genes silenced in QBC cells Chinese-German J Clin Oncol 7 627 630
14. H Li 2009 Effects of hydralazine and valproate on the expression of E-cadherin gene and the invasiveness and the invasiveness of QBC939 cells Frontiers Med China 3 153 157
15. M Candelaria 2007 A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann Oncol 18 1529 1538 (Pubitemid 47365487)
16. C Arce 2006 A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer PLoS ONE 1 e98
17. A Duenas-Gonzalez M Candelaria C Perez-Plascencia 2008 Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors Cancer Treat Rev 34 206 222
18. P Zambrano 2005 A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes BMC Cancer 5 44
19. CJ Phiel 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 36734 36741
20. OH Kramer 2003 The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 EMBO J 22 3411 3420 (Pubitemid 36834871)
21. A Chávez-Blanco 2005 Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study Mol Cancer 4 22
22. G Bug 2005 Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia Cancer 104 2717 2725 (Pubitemid 41798282)
23. GB García-Manero 2006 Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia Blood 108 3271 3279
24. ML de la Mora-Garcia 2006 Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid J Transl Med 4 55
25. E de la Cruz-Hernandez 2007 The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study Virol J 4 18
26. Candelaria M, et al. A pilot study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Eur J Gynecol Oncol (in press).
27. P Therasse 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
28. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010 Feb 26. [Epub ahead of print].
29. C Arce 2006 Hydralazine target: from blood vessels to the epigenome J Transl Med 4 10
30. HJ Long III 2005 Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study J Clin Oncol 23 4626 4633
31. K Appleton 2007 Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors J Clin Oncol 25 4603 4609 (Pubitemid 350035319)
32. JA Gollob 2006 Phase I trial of sequential low-dose 5-aza-2'- deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma Clin Cancer Res 12 4619 4627 (Pubitemid 44297813)
33. DJ Stewart 2009 Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas Clin Cancer Res 15 3881 3888
34. N Singh A Dueñas-González F Lyko JL Medina-Franco 2009 Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1 Chem Med Chem 4 792 799
35. G Howard R Eiges F Gaudet R Jaenisch A Eden 2008 Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice Oncogene 27 404 408
36. FH Gaudet 2003 Induction of tumors in mice by genomic hypomethylation Science 300 489 492
37. D Kuck N Singh F Lyko JL Medina-Franco 2010 Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation Bioorg Med Chem 18 822 829
38. AI Daud J Dawson R DeConti 2009 Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial Clin Cancer Res 15 2479 2487
39. P Munster 2009 Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC Clin Cancer Res 15 2488 2496
40. MT Voso 2009 Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes Clin Cancer Res 15 5002 5007
41. F Braiteh 2008 Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers Clin Cancer Res 14 6296 6301
42. J Lin 2009 A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors Clin Cancer Res 15 6241 6249